Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS
Portfolio Pulse from Vuk Zdinjak
Tryp Therapeutics has submitted an Investigational New Drug application to the FDA for a phase 2a clinical trial of psilocybin-assisted psychotherapy in treating patients with irritable bowel syndrome (IBS) at Massachusetts General Hospital. The study will be conducted in collaboration with Harvard Medical School/Massachusetts General Hospital.
May 24, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tryp Therapeutics submits IND application to FDA for phase 2a clinical trial of psilocybin-assisted psychotherapy in IBS patients, potentially opening a new treatment avenue.
The submission of the IND application to the FDA is a significant step for Tryp Therapeutics, as it could potentially open a new treatment avenue for IBS patients. If the clinical trial is successful, it may lead to increased demand for Tryp's products and services, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100